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Background: COPD is often associated with cardiovascular comorbidity. Treatment guidelines 
recommend therapy with bronchodilators as first choice. We investigated the acute effect of 
single-dose indacaterol on lung hyperinflation in COPD subjects, for the first time evaluating 
the potential effects on right heart performance.
Methods: In this Phase IV, randomized, interventional, double-blind, crossover clinical 
study, we recruited 40 patients (50–85 years of age) with stable COPD. Patients were treated 
with 150 μg indacaterol or placebo and after 60 minutes (T60) and 180 minutes (T180) the 
following tests were performed: trans-thoracic echocardiography (TTE), plethysmography, 
diffusing capacity of the lung for carbon monoxide, saturation of peripheral oxygen, and 
visual analog scale dyspnea score. Patients underwent a crossover re-challenge after a fur-
ther 72 hours of pharmacological washout. All TTE measurements were conducted blindly 
by the same operator and further interpreted by two different blinded operators. Consensus 
decisions were taken on every value and parameter. The primary outcome was the effect 
of the reduction of residual volume and functional residual capacity on right heart systolic 
and diastolic function indexes evaluated by TTE in patients treated with indacaterol, as 
compared to placebo.
Results: Vital capacity, inspiratory capacity, and forced expiratory volume in 1 second were 
significantly increased by indacaterol, when compared with placebo, while residual volume, 
intrathoracic gas volume, and specific airway resistance were significantly reduced in patients 
treated with indacaterol. Tricuspid annular plane systolic excursion was significantly increased 
versus placebo, paralleled by an increase of tricuspid E-wave deceleration time. The cardiac 
frequency was also significantly reduced in indacaterol-treated patients.
Conclusion: Indacaterol significantly reduces lung hyperinflation in acute conditions, with a 
clinically relevant improvement of dyspnea. These modifications are associated with a signifi-
cant increase of the right ventricular compliance indexes and may have a role in improving left 
ventricular preload leading to a reduction in cardiac frequency.
Keywords: lung deflation, bronchodilator, cardiac performance, right ventricular function, 
echocardiography
Introduction
COPD is characterized by persistent airflow limitation, pulmonary hyperinflation, and 
impaired ventilation homogeneity. COPD is often associated with various comorbidi-
ties, mainly cardiovascular and metabolic in nature, and ranks third among the causes 
of death worldwide.1
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A form of COPD is chronic obstructive bronchitis, 
causing narrowed airways, persistent cough, and excess 
mucus production. Severe COPD partially overlaps with 
emphysema, accompanied by destruction of alveolar walls 
and permanent enlargement of lung regions. The loss of lung 
parenchyma and the supporting elastic structures leads to the 
loss of pulmonary elastic recoil. This causes increased resis-
tance, airflow obstruction, air trapping, and lung hyperinfla-
tion. This frequently results in dyspnea which is responsible 
for the limitation of daily activities in COPD patients.2,3
The correlation between emphysema and altered left 
ventricular (LV) end-diastolic volume is well established.4,5 
Notwithstanding, little is known about the effects of these 
alterations on heart mechanical functions. The large Multi-
Ethnic Study of Atherosclerosis (MESA) study, combining 
measurements of right ventricular (RV) structure and func-
tion with assessment of emphysema, showed that percent 
emphysema was inversely correlated to RV end-diastolic 
volumes, stroke volume, and mass, likely associated with 
increased lung vascular resistance and pulmonary hyperin-
flation.6 A frequent complication of very severe COPD is 
cor pulmonale, a structural alteration with function impair-
ment of the right ventricle, leading to increased pulmonary 
vascular resistance and right heart failure. This condition 
is accompanied by the reductions in LV filling, LV stroke 
volume, and cardiac output, while left ventricular ejection 
fraction (LVEF) is usually maintained.4 A study conducted 
on a large cohort of patients with heart failure, either with 
preserved or with reduced LVEF, evaluated prevalence and 
prognostic impact of the noncardiac comorbidities in the 
two groups. The result of this survey revealed that COPD 
was the sole comorbidity significantly associated with an 
higher hazard for mortality in patients with preserved EF, 
although COPD was an independent predictor of mortality 
in both the groups.7 These studies highlight the importance 
of investigating the relationships between heart and lung 
structure and function.
COPD has been treated with bronchodilators and corticos-
teroids and for the last two decades long-acting β2-agonists 
(LABAs) have been the mainstay of the management of COPD, 
according to the guidelines of the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD).3 These agents relax airway 
smooth muscle and augment expiratory airflow, with reduced 
hyperinflation and improvement of dyspnea, functional 
capacity, and patient quality of life. More recently, ultra- 
LABAs, like the novel once-daily LABA indacaterol,8 have 
been also approved for COPD. They have an ultra-long dura-
tion of action (at least 24 hours) and rapid bronchodilation 
activity (within 5 minutes).9 Several clinical studies revealed 
that indacaterol has comparable or even superior clinical 
efficacy than the previously available LABAs.10–17
Aim of the study reported here was to evaluate the acute 
effect of a single-dose of the long-acting β2 agonist inda-
caterol 150 μg on lung hyperinflation in COPD subjects with 
lung air trapping, and the consequent potential effects on right 
heart systolic and diastolic functional indexes.
Materials and methods
study design and patients
This was a Phase IV, monocentric, randomized, prospective, 
interventional, double-blind, placebo-controlled, crossover 
study. The protocol was approved by the Central Ethic 
Committee (CEC) of the Salvatore Maugeri Foundation. All 
patients provided their written informed consent.
The main inclusion criteria were patients aged 50–85 years, 
former or active smokers with a history of COPD of at least 
1 year and defined according to GOLD 2013 criteria,3 
clinically stable in the last 3 months, with forced respiratory 
volume in 1 second (FEV
1
) pred #70% and a residual volume 
(RVo) pred $135%, and absence of cardiac comorbidities.
Procedures
Between November 2013 and October 2014, we recruited and 
enrolled a total of 40 eligible patients with COPD. Patients 
were randomly allocated in a 1:1 ratio to receive either 150 μg 
indacaterol or placebo. Following the washout of the inhalation 
therapy (T0), patients were treated with 150 μg indacaterol or 
placebo. After 60 minutes (T60) and 180 minutes (T180) the 
following tests were performed: trans-thoracic echocardiog-
raphy (TTE), plethysmography, diffusing capacity of the lung 
for carbon monoxide, saturation of peripheral oxygen, and 
visual analog scale (VAS) dyspnea score. The VAS dyspnea 
score ranged from 0 (no dyspnea at rest) to 10 (unbearable 
dyspnea) and it was recorded by the same blinded operator. 
Patients underwent a crossover re-challenge after a further 72 
hours of pharmacological washout (Figure 1).
All echocardiography examinations were performed with 
a GE Vivid 7 Dimension ultrasound system (GE HealthCare 
UK Ltd, Little Chalfont, UK). A complete standard M-mode 
and two-dimensional echocardiography examinations were 
performed according to our clinical laboratory practice using 
a S5-1 sector array probe. All measurements were made on 
three representative beats and the results were averaged. The 
following parameters were evaluated to study right heart size 
and systolic and diastolic function: RV size, right atrial size, 
RVEF, tricuspid annular plane systolic excursion (TAPSE), 
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systolic pulmonary artery pressure (sPAP) with an estimate 
of right atrial pressure on the basis of inferior vena cava size 
and collapse, tricuspid E/A ratio, tricuspid E/e’ ratio, and 
tricuspid E-wave deceleration time (DT-TR). Left heart size 
and systolic and diastolic function were evaluated as follows: 
LV size, left atrial (LA) size, LVEF, mitral valve peak E and 
peak A, E/A mitral ratio, E/e’ mitral ratio, mitral E-wave 
deceleration time (DT-MR).
TAPSE was expressed in millimeters (mm), while 
measurements of DT-TR and DT-MR were expressed in 
milliseconds (msec).
Heart rate (HR) was recorded during all echocardio-
graphic maneuvers.
Outcomes
The primary outcome was to evaluate the reduction of RVo 
and functional residual capacity induced by indacaterol and 
its effect on the following right cardiac systolic and diastolic 
functional indexes: RVEF, TAPSE, sPAP, tricuspid E/e’ 
ratio, and DT-TR.
Additional outcomes after indacaterol treatment were 
the evaluation of: 1) interventricular septum motility 
modification; 2) modifications in cardiac LVEF, E/e’ mitral 
ratio, DT-MR; and 3) right cardiac chambers kinetics 
modifications by TTE. Inspiratory capacity modifications 
and specific airway resistance (sRAW) were assessed by 
body plethysmography and spirometry.
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Figure 1 Consolidated Standards of Reporting Trials (CONSORT) 2010 flow diagram.
Notes: The diagram graphically outlines the design and conduct of the clinical study.
Abbreviations: DlCO, diffusing lung capacity for carbon monoxide; spO2, peripheral oxygen saturation; TTe, trans-thoracic echocardiography; Vas, visual analog scale.
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statistical analysis
Statistical analyses were performed using SSPS (v 20.0; IBM 
Corporation, Armonk, NY, USA). Results were analyzed using 
the t-test for unpaired data with α=0.05. All results were also 
compared using the t-test for paired data after analysis of cova-
riance and Bonferroni correction was applied. Any difference 
with P#0.05 was considered significant. All values are pre-
sented as mean ± standard deviation, unless otherwise stated. 
The reported work was a pilot study; therefore, sample size 
was not calculated by power analysis, because of the absence 
of any data in the literature that could be reviewed. The trial is 
registered with ClinicalTrials.gov, number NCT01996124.
Results
This study has been conducted on a total of 40 COPD 
patients, from November 2013 to October 2014. Patients’ 
demographics and baseline variables of lung functionality 
are reported in Table 1.
The dynamic respiratory parameters, vital capacity 
(VC), inspiratory capacity (IC), and FEV
1
 were recorded 
in all subjects under study by spirometric measurements at 
baseline (T0) and after 60 minutes (T60) and 180 minutes 
(T180) of indacaterol 150 μg inhalation. Values are expressed 
as volumes (L) and as percent predicted (% pred) as well. 
For all three parameters examined indacaterol 150 μg treat-
ment induced a significant increase, both at T60 and T180, 
as compared with T0. Particularly relevant increases of 
volumes were observed at T180 for VC, IC, and FEV
1
. The 
differences were statistically significant also when calculated 
versus the treatment with placebo (Table 2). No significant 
modifications were found in the diffusing capacity of the 
lung for carbon monoxide and its subcomponents (alveolar 
volume and transfer coefficient) both after indacaterol and 
placebo treatment (data not shown).
As regards the static respiratory parameters, total lung 
capacity, RVo, intrathoracic gas volume (ITGV, a plethys-
mographic equivalent to functional residual capacity), and 
sRAW were evaluated by plethysmography. As in the case 
of dynamic volumes, the treatment with indacaterol 150 μg 
provided the patients with a significant benefit, both at T60 
and at T180. All parameters considered, total lung capacity, 
RVo, ITGV, and sRAW were significantly reduced, both 
when compared to T0 and placebo treatment (Table 3).
Following the evaluation of respiratory function param-
eters, TTE was performed.
With regard to right cardiac chambers, no changes in 
RVEF, sPAP mitral valve peak E and peak A, E/A mitral 
ratio, and E/e’ mitral ratio were found.
After indacaterol, at T180 a significant increase of 
TAPSE was observed compared to T0, while at T60 the 
increase was significant when compared to the patients 
treated with placebo. In parallel, after indacaterol the 
DT-TR was significantly increased at T60 and T180 both 
Table 1 Demographic, anthropometric, and baseline lung 
function variables
Variable Actual  
value
Percent of predicted 
values
study participants, n 40
age, years 71.6±7.10
sex, M/F 27/13
height, m 1.64±0.10
Weight, kg 65.80±15.9
BMI 24.60±5.10
smoking history, pack-years 41.20±10.60
gOlD stage I–II, n 0–10
gOlD stage III–IV, n 13–17
FeV1, l 0.96±0.43 41.40±17.20
VC, l 2.71±0.85 86.70±15.70
rVo, l 4.70±1.34 201.40±59.20
room air spO2 92.60±2.30
hr, bpm 71.60±10.50
Vas dyspnea score 1.40±1.90
Note: Data are shown as mean ± standard deviation.
Abbreviations: BMI, body mass index; FeV1, forced expiratory volume in 1 second; 
gOlD, global Initiative for Chronic Obstructive lung Disease; hr, heart rate; rVo, 
residual volume; spO2, peripheral capillary oxygen saturation; Vas, visual analog 
scale; VC, vital capacity; bpm, beats per minute.
Table 2 Dynamic respiratory parameters after 60 and 180 minutes’ treatment with indacaterol or placebo
Parameter Indacaterol Placebo
T0 ΔT60 ΔT180 T0 ΔT60 ΔT180
IC, l 1.94±0.64 +0.14±0.35#,* +0.12±0.31#,* 1.91±0.63 +0.03±0.24 +0.02±0.22
IC, % pred 84.94±21.50 +9.51±22.91#,* +7.85±17.54#,* 83.7±21.70 +1.02±6.30 +0.90±5.90
VC, l 2.71±0.85 +0.16±0.25#,* +0.22±0.27#,* 2.70±0.87 +0.01±0.14 -0.04±0.21
VC, % pred 86.68±15.69 +6.85±9.75#,* +9.00±10.58#,* 87.05±15.23 +0.80±3.80 -0.50±4.20
FeV1, l 0.96±0.43 +0.07±0.12#,* +0.08±0.13#,* 0.94±0.46 -0.01±0.16 +0.01±0.15
FeV1, % pred 41.45±17.16 +7.75±10.9#,* +7.66±11.53#,* 40.65±17.16 +0.80±3.10 +0.20±4.50
Vas dyspnea 1.40±1.90 -0.48±1.01#,* -0.80±1.30#,* 1.30±1.92 -0.20±0.55 -0.25±1.15
Notes: Data are shown as mean ± standard deviation. #P#0.05 vs T0 (baseline); *P#0.05 vs placebo. Δ = post-(T60 and T180) (60 and 180 minutes) minus pretreatment (T0) values.
Abbreviations: FeV1, forced expiratory volume in 1 second; IC, inspiratory capacity; VC, vital capacity; Vas, visual analog scale; % pred, percent predicted.
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Table 3 static respiratory parameters after 60 and 180 minutes’ treatment with indacaterol or placebo
Parameter Indacaterol Placebo
T0 ΔT60 ΔT180 T0 ΔT60 ΔT180
TlC, l 7.36±1.41 -0.32±0.75* -0.27±0.92* 7.33±1.39 -0.04±0.82 +0.03±0.85
TlC, % pred 130.61±22.65 -1.10±4.37* -2.58±11.52* 129.50±21.87 +0.20±5.20 +0.90±9.87
rVo, l 4.70±1.34 -0.48±0.85#,* -0.56±1.03#,* 4.74±1.31 -0.02±0.90 +0.04±0.98
rVo, % pred 201.42±59.25 -8.61±13.44#,* -9.14±16.62#,* 205.28±60.08 -1.20±14.52 +1.14±15.9
ITgV, l 5.50±1.42 -0.43±6.55#,* -0.54±0.91#,* 5.53±1.41 -0.06±7.82 +0.01±0.95
ITgV, % pred 174.92±45.01 -6.55±10.97#,* -7.81±12.36#,* 176.47±44.87 +1.2±11.12 -0.01±11.49
sraW, kPa/s 4.31±2.39 -0.75±0.87#,* -0.68±0.85#,* 4.26±2.28 -0.07±0.90 +0.02±0.80
sraW, % pred 393.22±219.26 -14.40±21.29#,* -13.11±18.02#,* 390.14±221.20 -0.80±16.42 +0.60±18.26
Notes: Data are shown as mean ± standard deviation. #P#0.05 vs T0 (baseline); *P#0.05 vs placebo. Δ = post-(T60 and T180) (60 and 180 minutes) minus pretreatment 
(T0) values.
Abbreviations: ITGV, intrathoracic gas volume; kPa/s, kilopascal per second; RVo, residual volume; sRAW, specific airway resistance; TLC, total lung capacity; % pred, 
percent predicted.
Table 4 Cardiac performance after 60 and 180 minutes’ treatment with indacaterol or placebo
Parameter Indacaterol Placebo
T0 ΔT60 ΔT180 T0 ΔT60 ΔT180
TaPse, mm 22.30±3.52 +0.05±1.28* +0.41±1.07#,* 21.90±3.83 -0.03±1.26 +0.02±3.80
PaPs, mmhg 33.03±8.10 +0.71±5.50 -0.08±7.76 32.78±8.30 +0.77±4.46 +0.24±5.76
DT-Tr, msec 207.80±64.90 +9.93±36.31* +11.90±32.86#,* 206.70±65.84 +2.60±35.90 +3.80±38.90
lVeF, % 61.80±5.25 -0.03±1.90 -0.25±2.20 60.60±6.21 +0.09±2.12 -0.14±2.35
DT-Mr, msec 230.18±58.69 +3.98±38.24 +4.33±38.79 228.25±59.33 +1.12±37.52 +1.38±36.81
hr, bpm 71.54±10.60 -1.95±5.30#,* -2.00±6.10#,* 70.21±9.40 -0.80±1.20 +0.60±1.30
Notes: Data are shown as mean ± standard deviation. #P#0.05 vs T0 (baseline); *P#0.05 vs placebo. Δ = post-(T60 and T180) (60 and 180 minutes) minus pretreatment 
(T0) values.
Abbreviations: bpm, beats per minute; DT-Tr, tricuspid e-wave deceleration time; hr, heart rate; lVeF, left ventricular ejection fraction; DT-Mr, mitral e-wave deceleration 
time; msec, milliseconds; PaPs, systolic pulmonary artery pressure; TaPse, tricuspid annular plane systolic excursion.
versus T0 and placebo. HR was significantly reduced after 
treatment with indacaterol at all time points, while no 
significant variations were observed after treatment with 
placebo (Table 4).
No changes in LV function parameters were detected. In 
particular, LVEF together with mitral valve function param-
eters were not significantly modified both after indacaterol 
and placebo treatment.
Dyspnea evaluated with VAS score was significantly 
reduced after indacaterol at every time point as compared 
both to baseline and placebo (Table 2).
Discussion
This Phase IV, randomized, interventional study focused 
on the potential positive effect of indacaterol on the cardiac 
functions of COPD patients, based on two previous relevant 
advances in the field. On one hand, recent data reported the 
acute effects of indacaterol in reducing lung hyperinflation 
(inducing lung deflation) and alleviating dyspnea perception 
at rest in COPD patients.19 On the other hand, it has been 
shown that severe COPD with emphysema with the associ-
ated hyperinflation plays a key role on heart size reduction 
and cardiac dysfunction.4,5
Moreover, COPD was shown to be the sole comorbidity 
significantly associated with an increased risk of mortality 
in patients with heart failure, irrespective of the condition of 
the EF.7 This evidence further underscores the importance 
of preserving lung structure and function to improve heart 
conditions. Therefore, we hypothesized that the treatment of 
hyperinflated COPD patients with indacaterol, with its acute 
effect on lung deflation, may positively influence the cardiac 
parameters and the functionality of the right heart in particu-
lar. Given that the main effect of lung deflation induced by 
indacaterol is a decrease of RVo with consequent increase 
of IC, a RVo pred $135% was the most important criterion 
among the inclusion criteria of this study.
The inter-operator variability of echocardiography evalu-
ations was overruled by the fact that all echocardiography 
measurements were conducted blindly by the same opera-
tor on all the patients under study and interpreted by two 
different blinded operators who discussed all the data and 
consequently consensus decision was taken in account.18 This 
procedure has been previously demonstrated to bring inter-
observer variability close to zero.19 The aim of the cardiac 
performance study was mechanical, not electric, functionality 
(no electrocardiograms were performed).
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In agreement with previously reported outcomes,20,21 
the results of this study reveal that indacaterol significantly 
reduces lung hyperinflation versus placebo in acute condi-
tions, and leads to a clinically relevant improvement in 
dyspnea perception at rest in COPD patients. These positive 
effects are accompanied by a significant increase in RV com-
pliance. After 180 minutes following indacaterol inhalation, 
TAPSE and DT-TR show a significant improvement.
Moreover, a statistically significant reduction of cardiac 
frequency was observed. This is particularly relevant because 
it was accompanied by a concomitant reduction in dyspnea, 
which parallels lung deflation. The mechanical effort of 
accessory respiratory muscles during patient respiration 
was consequently reduced, as was the needed heart output. 
The reduction of transparietal pressure appears to play an 
important role in improving diastolic right cardiac indexes22 
and together with the reduced work of breathing may be 
responsible for the reduction in HR. In one of the first studies 
to make a complete echocardiographic assessment of COPD 
patients, Boussuges et al23 described a reduced LV preload in 
COPD patients that could be secondary to many factors, such 
as increased HR, increased positive end expiratory pressure 
(PEEP), chronic hypoxia24 and relative hypovolemia. The 
reduced right venous return secondary to PEEP increase 
can be therefore responsible for an impaired LV filling and 
increased cardiac frequency. All the patients in our study had 
chronic hypoxemia, that may be, per se, indirectly responsible 
for impaired LV preload (mean saturation of peripheral oxy-
gen 92.6%, Table 1). In our study, by reducing hyperinflation, 
and therefore PEEP, we favor the right venous return, thus 
possibly influencing the diastolic filling pattern of the left 
ventricle and allowing a reduction in HR.
Unfortunately, we were not able to measure any changes 
in diastolic and systolic LV indexes. This might be due 
to two major issues: the first one may rely on the higher 
working pressures of the LV, therefore being affected to 
a lesser extent by the variations of intrathoracic pressure 
than the RV, thus leading to smaller measurable changes. 
Secondly, taking in to account the observation made earlier 
and the previous literature on the topic, echocardiography 
may not represent the most sensible tool in detecting the tiny 
changes that occur in the left heart chambers, especially in 
hyperinflated patients with air trapping. Indacaterol has a 
well-known good safety profile,11 although potentially leads 
to tachycardia25,26 that, however, was not recorded for any 
patients of the present study.
Our study focused on acute effects only and this may 
be viewed as a limitation. However, as far as we are aware, 
this is the first study on the effect of indacaterol on the heart 
function of COPD patients, and, given the positive acute 
effects observed, it can be the starting point for further long-
term studies on the effect of pulmonary deflation on heart 
functionality.
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